Cargando…
Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4(+)CD45RB(high) T cells
Amiselimod (MT-1303) is a novel sphingosine 1-phosphate receptor-1 (S1P(1) receptor) modulator with a more favorable cardiac safety profile than other S1P(1) receptor modulators. MT-1303 phosphate (MT-1303-P), an active metabolite of MT-1303, exhibits S1P(1) receptor agonism at a lower EC(50) value...
Autores principales: | Shimano, Kyoko, Maeda, Yasuhiro, Kataoka, Hirotoshi, Murase, Mikako, Mochizuki, Sachiko, Utsumi, Hiroyuki, Oshita, Koichi, Sugahara, Kunio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894856/ https://www.ncbi.nlm.nih.gov/pubmed/31805144 http://dx.doi.org/10.1371/journal.pone.0226154 |
Ejemplares similares
-
Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models
por: Sugahara, Kunio, et al.
Publicado: (2019) -
Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
por: Sugahara, Kunio, et al.
Publicado: (2016) -
A New Phenylpyrazoleanilide, Y-320, Inhibits Interleukin 17 Production and Ameliorates Collagen-Induced Arthritis in Mice and Cynomolgus Monkeys
por: Ushio, Hiroyuki, et al.
Publicado: (2013) -
Two-year results from a phase 2 extension study of oral amiselimod in
relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2017) -
Upgrading of high power klystron YK1303
por: Isagawa, S, et al.
Publicado: (1994)